NTAN1 and neoplasm: [80] showed that a monoclonal anti-body (MHA112) that can specifically bind with peripheral lymph node address protein (PNAd) highly expressed in LN or tumor stroma was found can greatly enhance the targeting efficiency of antibody-conjugated drugs to tumor and tdLNs simultaneously.